A Randomized, Double-Blind, Placebo-Controlled, Analytically Masked Sequential-Panel, Ascending Single-Dose, and Repeated Twice Daily-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Analgesic Efficacy of Oral CMX-020 in Healthy Male and Female Subjects.
Phase of Trial: Phase I
Latest Information Update: 24 Jun 2016
At a glance
- Drugs CMX 020 (Primary)
- Indications Neuropathic pain; Postoperative pain
- Focus Adverse reactions
- 07 Aug 2015 Status changed from active, no longer recruiting to completed, as reported by Australian New Zealand Clinical Trials Registry
- 04 Jun 2015 Status changed from recruiting to active, no longer recruiting as per Australian New Zealand Clinical Trials Registry.
- 17 Apr 2015 New trial record